Protein aggregation is common to dozens of diseases including prionoses, diabetes,
Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in …

Alzheimer's disease (AD) challenges our society with an annual estimated cost of $1.08
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …

Increasing evidence has suggested that formation and propagation of misfolded aggregates
of 42-residue human amyloid β (Aβ (1–42)), rather than of the more abundant Aβ (1–40) …

Our understanding of the molecular structures of amyloid fibrils that are associated with
neurodegenerative diseases, of mechanisms by which disease-associated peptides and …

Amyloidogenesis has been implicated in a broad spectrum of diseases in which amyloid
protein is invariably misfolded and deposited in cells and organs. Alzheimer's disease is one …

Alzheimer's disease (AD) pathology is characterized by plaques of amyloid beta (Aβ) and
neurofibrillary tangles of tau. Aβ aggregation is thought to occur at early stages of the …

Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of
toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and …

In Alzheimer's disease (AD), soluble oligomers of amyloid-β (Aβ) are emerging as a crucial
entity in driving disease progression as compared to insoluble amyloid deposits. The lacuna …

It is known that oligomers of amyloid-β (Aβ) peptide are associated with Alzheimer's disease.
Aβ has two isoforms: Aβ40 and Aβ42. Although the difference between Aβ40 and Aβ42 is …

Self-assembly of amyloid-β (Aβ) peptides in human brain tissue leads to neurodegeneration
in Alzheimer's disease (AD). Amyloid fibrils, whose structures have been extensively …